Fed. Circ. Unsure If PTAB Has To Explain Axing Avastin Patent

Law360, Washington (July 11, 2019, 10:36 PM EDT) -- The Federal Circuit appeared skeptical Thursday that drugmaker Genentech deserves a beefier explanation from the Patent Trial and Appeal Board about why it axed a patent covering the company's blockbuster cancer drug Avastin.

Genentech Inc. attorney Thomas S. Fletcher said during a brief hearing that the board is required to explain why it rejected the company's proposed definition of a key term in one of the claims Hospira Inc. successfully challenged. Fletcher called the board's own definition, which he said wasn't introduced until it issued its final written decision, too vague.

U.S. Chief Circuit Judge Sharon Prost cut right to the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Appellate - Federal Circuit

Nature of Suit

Date Filed

May 11, 2018

Law Firms

Companies

Government Agencies

Patents